Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 1.00 |
| ▸ | S1PR3 | Q99500 | 14/20 | 1.00 |
| ▸ | S1PR4 | O95977 | 5/20 | 1.00 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 1.00 |
| ▸ | S1PR2 | O95136 | 3/20 | 1.00 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.70 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.70 |
| ▸ | TNNC1 | P63316 | 2/20 | 0.68 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.68 |
| ▸ | GPR183 | P32249 | 1/20 | 0.68 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fty720-P SCHEMBL80475 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| Fty720-P SCHEMBL1497894 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| Fty720-P SCHEMBL21225364 | 0.99 | S1PR1 (0.98) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL6510046 | 0.96 | S1PR1 (0.93) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL6502776 | 0.96 | S1PR1 (0.93) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL6502028 | 0.96 | S1PR1 (0.93) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL6529417 | 0.95 | S1PR1 (0.91) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| Fty720P SCHEMBL30239630 | 0.95 | S1PR1 (0.91) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| Fty720-P SCHEMBL13777289 | 0.92 | S1PR1 (0.84) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL6503014 | 0.92 | S1PR1 (0.84) | S1PR1S1PR3S1PR4S1PR5S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315735-A4 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO INC (US) | 2005-04-06 | — | — | EP | claimed |
| EP-1315735-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | Merck & Co., Inc. (US) | 2003-06-04 | — | — | EP | claimed |
| US-6437165-B1 | USEFUL FOR TREATING IMMUNE MEDIATED DISEASES AND CONDITIONS, SUCH AS BONE MARROW, ORGAN AND TISSUE TRANSPLANT REJECTION. | MERCK & CO., INC. | 2002-08-20 | — | — | US | claimed |
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | MERCK & CO., INC. | 2002-07-11 | — | — | US | claimed |
| WO-2002018395-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO., INC. (US) | 2002-03-07 | — | — | WO | claimed |
| CN-121909974-A | Method for improving development capacity of frozen IVF embryo of pig | 中国农业科学院北京畜牧兽医研究所 | 2026-04-24 | — | — | CN | disclosed |
| US-20260014176-A1 | Structurally and Functionally Repaired Endothelial Glycocalyx | UNIV NORTHEASTERN (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250333489-A1 | EPO VARIANTS AND MODULATORS | ANDREMACON S.R.L. (IT) | 2025-10-30 | — | — | US | disclosed |
| EP-4637819-A1 | METHODS OF TREATING INFLAMMATORY DISEASES WITH COMBINATION OF TL1A INHIBITORS AND S1PR INHIBITORS | Prometheus Biosciences, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250229007-A1 | UNIAXIALLY-ALIGNED NANOFIBER SCAFFOLDS AND METHODS FOR PRODUCING AND USING SAME | ORIDIVUS LLC | 2025-07-17 | — | — | US | disclosed |
| US-12357622-B2 | Pharmaceutical composition of S1PR modulators | UNIVERSITA DEGLI STUDI DI FIRENZE (IT) | 2025-07-15 | — | — | US | disclosed |
| US-20250177115-A1 | COMBINATORIAL THERAPIES INCLUDING IMPLANTABLE DAMPING DEVICES AND THERAPEUTIC AGENTS FOR TREATING A CONDITION AND ASSOCIATED SYSTEMS AND METHODS OF USE | THE BRAIN PROT COMPANY PTY LTD (AU) | 2025-06-05 | — | — | US | disclosed |
| US-20120244071-A1 | FTY720 HALOGENATED DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| US-20120244071-A1 | FTY720 HALOGENATED DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| EP-1660449-B1 | AMINOPROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| EP-1315735-A4 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO INC (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1315735-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | Merck & Co., Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6437165-B1 | USEFUL FOR TREATING IMMUNE MEDIATED DISEASES AND CONDITIONS, SUCH AS BONE MARROW, ORGAN AND TISSUE TRANSPLANT REJECTION. | MERCK & CO., INC. | 2002-08-20 | — | — | US | disclosed |
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | MERCK & CO., INC. | 2002-07-11 | — | — | US | disclosed |
| WO-2002018395-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO., INC. (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014176-A1 | Structurally and Functionally Repaired Endothelial Glycocalyx | APOB, APOL1, SELP | S1PR1 14/4885S1PR3 24/4885S1PR4 28/4885 |
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | ALPP, PPIP5K2, ALPI | S1PR1 382/4885S1PR3 520/4885S1PR4 499/4885 |
| US-12357622-B2 | Pharmaceutical composition of S1PR modulators | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885S1PR4 5/4885 |
| US-20120244071-A1 | FTY720 HALOGENATED DERIVATIVES | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885S1PR4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.